Last Updated : April 27, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area Sort ascending | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Omvoh | mirikizumab | Ulcerative colitis | Reimburse with clinical criteria and/or conditions | Complete | ||
| Simponi | Golimumab | Ulcerative colitis | Do not list at the submitted price | Complete | ||
| Humira | Adalimumab | ulcerative colitis | Withdrawn | |||
| Remicade | Infliximab | Ulcerative Colitis | Do not list | Complete | ||
| Cortiment | Budesonide | Ulcerative Colitis | Do not reimburse | Complete | ||
| Remsima | infliximab | Ulcerative Colitis | Active | |||
| Genotropin | Somatropin | Turner Syndrome | List with criteria/condition | Complete | ||
| N/A | everolimus | Tuberous Sclerosis Complex (TSC) | Active | |||
| Keytruda | pembrolizumab | Triple-negative breast cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
| Keytruda | pembrolizumab | Triple-negative breast cancer | Reimburse with clinical criteria and/or conditions | Complete |
Last Updated : April 27, 2024